Teplizumab and immune treatment for new diabetes diagnosis
Treatments studied
Part of Hormones & metabolism, Immune system & allergy clinical trials.
This early-stage trial is testing a new approach to slow or stop the loss of insulin-making cells in people who were recently diagnosed with type 1 diabetes. It uses a medicine called teplizumab to adjust the immune system, and the goal is to help you keep making your own insulin for as long as possible.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 45 years old.
- You must have been diagnosed with type 1 diabetes within the last 6 months.
- You must test positive for at least one diabetes-related autoantibody (a blood marker).
- Your insulin-making ability (C-peptide) must still be at a certain level.
- You must not have taken certain immune-suppressing medicines recently.
- You must not have active infections like HIV, hepatitis B or C, or tuberculosis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether teplizumab can help keep the body making insulin in people recently diagnosed with type 1 diabetes. It is for children and young adults aged 1 to 25, and compares the drug against a placebo.
This study compares two medicines (teplizumab and anti-thymocyte globulin) to see if they can delay the onset of type 1 diabetes in people who are at high risk but don't have symptoms yet. If you have certain diabetes-related antibodies in your blood, this trial might help keep full-blown diabetes away for longer.
This trial tests an experimental drug called teplizumab to see if it can slow down or stop type 1 diabetes from getting worse. It is for Japanese people aged 1 to 34 who have stage 2 type 1 diabetes (blood sugar is slightly abnormal but not yet full diabetes).
This trial tests whether giving your own regulatory T cells (a type of immune cell) back to you can help slow or stop the immune attack on your pancreas in type 1 diabetes. It is for people aged 8 to 65 who still make some insulin.
This trial tests a new medicine (rezpegaldesleukin) to see if it can help preserve the body's ability to make some insulin in people recently diagnosed with type 1 diabetes. It's for children and adults diagnosed within the past 100 days.
This study tests a low dose of a drug that calms the immune system, followed by either another immune drug or a blood pressure medicine, to see if they can help preserve the body's ability to make insulin in people recently diagnosed with type 1 diabetes. It may help keep your own insulin production going longer.
Hear when a new Autoimmune Diabetes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.